1046-1047 / 2437
Relapsed GBM after RT-TMZ
•
No widely accepted standard
–
Re-resection +/- carmustine wafers?
–
PCV?
–
VEGF inhibition +/- CCNU:
•
various regimes containing bevacizumab
•
cediranib negative
–
EGFR TK inhibitors
•
erlotinib associated with
reduced
PFS (van den Bent JCO 2009)
–
TMZ rechallenge +/- altered temozolomide scheduling?
–
Immune checkpoint inhibition
Opportunity to test novel agents